查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012663

過敏診斷市場：依檢測類型、技術、過敏原類型和最終用戶分類－2026年至2032年全球市場預測

Allergy Diagnostics Market by Test Type, Technology, Allergen Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，過敏診斷市值將達到 63 億美元，到 2026 年將成長至 66.7 億美元，到 2032 年將達到 98.6 億美元，複合年成長率為 6.61%。

主要市場統計數據
基準年 2025 63億美元
預計年份：2026年 66.7億美元
預測年份 2032 98.6億美元
複合年成長率 (%) 6.61%

簡要概述塑造現代過敏診斷策略的不斷變化的臨床需求和技術進步。

過敏診斷正處於臨床需求與技術創新交匯點，其驅動力包括過敏性疾病盛行率的上升、臨床醫生診斷意識的增強以及患者對標靶治療策略的需求。臨床醫生越來越依賴精準的診斷路徑來區分致敏和具有臨床意義的過敏反應，這使得高重複性和高品質的檢測在門診和住院環境中都顯得尤為重要。同時，檢測技術和檢查室自動化的進步正在拓寬可行的檢測選擇範圍，從而實現更精確的解讀並支持精準醫療的發展。

該系統整合了臨床、技術和營運趨勢，從根本上重組了診斷流程，實現了個人化過敏護理。

在技​​術成熟、臨床範式轉移和醫療服務模式演進的推動下，過敏診斷領域正經歷著一場變革。分子和成分解析度診斷正從小眾應用走向更廣泛的臨床應用，使臨床醫生能夠分析複雜的致敏譜，並更準確地預測嚴重過敏反應的風險。同時，檢測靈敏度和特異性的提高，以及多重檢測平台的日益普及，正在減少診斷的不確定性，並縮短治療決策的製定過程。

評估 2025 年關稅環境將如何重塑整個診斷價值鏈的供應鏈、採購行為和區域製造策略。

政策和貿易措施可能對整個診斷供應鏈產生顯著的連鎖反應，2025年宣布的關稅調整的累積影響將體現在製造、分銷和檢查室運營等各個環節。對進口試劑、儀器零件和耗材徵收關稅將推高依賴國際供應商的製造商的邊際生產成本，這可能導致標價上漲和合約條款下行壓力。對於檢查室和終端用戶而言，這意味著供應鏈韌性、庫存計劃以及與供應商簽訂長期合約的重要性日益凸顯。

深入了解將檢測方式、檢測技術、過敏原類別和最終用戶操作重點與商業性機會連結的目標細分。

細分市場洞察對於最佳化產品開發、商業化和部署策略至關重要。根據檢測類型，診斷途徑涵蓋了從皮內試驗和斑貼試驗等皮膚檢測方法到血清檢測方法（包括血清特異性IgE檢測和皮膚點刺試驗）等多種選擇。在血清分析中，化學化學冷光免疫檢測和酵素免疫分析法與傳統的放射性過敏原吸附試驗並存，每種方法在處理能力、靈敏度和檢查室相容性方面各有優劣。根據技術，市場還可以根據檢測方法的選擇進一步細分。化學冷光平台往往優先考慮自動化和靈敏度；酵素免疫分析法(ELISA) 為中型檢查室提供了柔軟性和成本效益；螢光酵素免疫分析法在某些配置下具有多重檢測的優勢；而放射性過敏原吸附試驗在維持既定工作流程的情況下仍然適用。

臨床實務、監管環境和基礎設施投資的區域差異如何導致全球市場出現不同的採用路徑。

區域趨勢對臨床實務和商業策略都有影響，因此在產品設計、監管合作和通路管理方面需要採取細緻入微的方法。在美洲，先進的血清檢測方法已廣泛應用於臨床，而檢查室網路集中化管理，並受到保險公司的嚴格監管。這就要求產品必須具備經證實的臨床效用，並且擁有高效率的報銷途徑。在歐洲、中東和非洲，不同的法規結構和檢查室能力意味著靈活的產品特性、本地夥伴關係關係以及對分散式檢查的支援可以加速產品的普及，而區域臨床指南則會影響過敏原檢測組合和檢測形式的優先順序。在亞太地區，醫療基礎設施的快速投資、都市區過敏性疾病盛行率的上升以及多樣化的監管途徑，為高通量集中式檢查室和適應當地臨床工作流程的照護現場（PoC）解決方案創造了機會。

決定哪家診斷服務提供者將在檢查室實施和整合到臨床指南方面佔據主導的關鍵競爭行動和策略重點。

過敏診斷領域的競爭格局由多元化的大型診斷公司、專業的過敏檢測套組製造商以及專注於創新和區域分銷的靈活利基企業組成。成熟的製造商正投資於自動化、多重檢測和數位化結果解讀，以實現產品組合的差異化，並滿足檢查室對效率和整合報告功能的需求。專業公司則著重宣傳其獨特的診斷化學技術和支持成分分解診斷的臨床證據，以促進過敏科醫生和三級醫療機構的採用。此外，契約製造和試劑供應商在維持供應連續性方面發揮著至關重要的作用，而且其重要性日益凸顯，尤其是在檢查室尋求能夠支持其在不斷變化的監管要求下進行驗證和品質保證的合作夥伴之際。

經營團隊應優先採取策略性舉措，加強過敏診斷領域的證據、互通性、供應彈性和市場准入的準確性。

產業領導者應優先考慮一系列切實可行的舉措，將市場動態轉化為永續的競爭優勢。首先，投資產生強力的臨床證據，不僅要證明分析效能，還要證明其臨床效用，從而指導治療決策並減少後續醫療資源的使用。其次，追求平台互通性，並與實驗室資訊系統和電子健康記錄深度整合，以簡化臨床醫生的工作流程，並透過決策支援創造價值。第三，探索雙重採購和區域生產安排，以實現供應鏈多元化，降低關稅風險，並確保關鍵試劑和儀器組件的持續供應。

採用透明的混合方法研究途徑，結合相關人員訪談、監管審查和技術檢驗，為策略建議提供支援。

本分析整合了嚴謹的混合方法檢查室，以及對同行評審文獻、監管指南和檢測套組製造商技術文件的系統性二次文獻回顧。主要研究著重於相關人員群體間的三角檢驗，檢驗了臨床工作流程、檢測偏好和推廣障礙。二次文獻則提供了有關技術性能特徵、報銷環境和過往監管先例的背景信息，指南對相關人員反饋的解讀和情景構建。

重點關注技術進步、臨床期望和供應限制之間的交集，並整合實用見解以支援策略決策。

過敏診斷正處於轉折點，隨著檢測技術的進步、臨床需求的演變以及供應鏈現實的交匯，過敏性疾病的識別和管理方式正在改變。檢測準確性的提高使得患者分層和標靶治療路徑的發展更加有效，而營運創新則擴大了檢測能力並縮短了反應時間。然而，貿易政策的變化以及監管和報銷框架的區域差異等外部壓力，要求我們制定前瞻性的策略，以增強供應鏈韌性、促進實證醫學的產生並實現本地化的商業化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 過敏診斷市場：檢測類型

  • 皮內試驗
  • 斑貼試驗
  • 血清特異性IgE檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 放射性過敏原檢測
  • 皮膚點刺試驗

第9章：過敏診斷市場：依技術分類

  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 螢光酵素免疫分析法
  • 放射性過敏原分選方法

第10章：依過敏原類型分類的過敏診斷市場

  • 接觸性過敏原
  • 藥物過敏原
  • 食物過敏原
  • 吸入性過敏原

第11章 過敏診斷市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院和診所

第12章 過敏診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 過敏診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 過敏診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國過敏診斷市場

第16章：中國過敏診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abnova Corporation
  • ACON Laboratories, Inc.
  • AESKU.GROUP GmbH
  • bioMerieux SA
  • Canon Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • EUROIMMUN Medizinische Labordiagnostika AG
  • HAL Allergy Group BV
  • Hitachi Chemical Diagnostics, Inc.
  • HOB Biotech Group Corp., Ltd.
  • Hollister Stier Allergy Inc.
  • Hycor Biomedical（GmbH）
  • HYCOR Biomedical Inc.
  • Laboratory Corporation of America Holdings
  • Lincoln Diagnostics, Inc.
  • Macro Array Diagnostics GmbH
  • Minaris Medical America, Inc.
  • Neogen Corporation
  • Omega Diagnostics Group PLC
  • Quest Diagnostics Incorporated
  • R-Biopharm AG
  • Siemens Healthineers AG
  • Stallergenes Greer International AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901065A32

The Allergy Diagnostics Market was valued at USD 6.30 billion in 2025 and is projected to grow to USD 6.67 billion in 2026, with a CAGR of 6.61%, reaching USD 9.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.30 billion
Estimated Year [2026] USD 6.67 billion
Forecast Year [2032] USD 9.86 billion
CAGR (%) 6.61%

A concise orientation to the evolving clinical imperatives and technological advances shaping modern allergy diagnostic strategies

Allergy diagnostics sits at the nexus of clinical need and technological innovation, driven by rising prevalence of allergic conditions, greater diagnostic awareness among clinicians, and patient demand for targeted management strategies. Clinicians increasingly rely on precise diagnostic pathways to distinguish sensitization from clinically relevant allergy, and this has elevated the importance of reproducible, high-quality testing across outpatient and hospital settings. Concurrently, advances in assay technologies and laboratory automation have expanded the range of viable options, enabling more nuanced interpretations and supporting precision therapeutics.

Healthcare systems are also responding to pressures to reduce avoidable emergency visits and improve chronic disease management, which positions accurate and rapid allergy diagnostics as a cost-effective clinical tool in broader care pathways. Payers and procurement teams are seeking evidence of clinical utility, operational efficiency, and interoperability with electronic health records, prompting vendors and laboratories to prioritize validation, standardization, and reporting clarity. Taken together, these dynamics frame the immediate priorities for stakeholders seeking to invest in or adopt allergy diagnostic solutions.

How converging clinical, technological, and operational trends are fundamentally reshaping diagnostic pathways and enabling personalized allergy care

The landscape of allergy diagnostics is undergoing transformative shifts prompted by technological maturation, changing clinical paradigms, and evolving healthcare delivery models. Molecular and component-resolved diagnostics have moved from niche applications toward broader clinical acceptance, enabling clinicians to parse complex sensitization profiles and better predict risk for severe reactions. At the same time, improvements in assay sensitivity and specificity, alongside growing availability of multiplex platforms, are reducing diagnostic ambiguity and shortening the route to therapeutic decisions.

Operationally, diagnostic laboratories are adopting higher degrees of automation and digital integration, which improves throughput and reduces turnaround time while supporting consistent quality control. The rise of point-of-care initiatives and decentralized testing pathways reflects a broader trend toward shifting appropriate care closer to patients. Additionally, the integration of diagnostic outputs with clinical decision support tools is gaining traction, providing clinicians with evidence-based recommendations informed by test results, comorbidity profiles, and exposure histories. These convergent shifts are recasting the role of allergy diagnostics from confirmatory testing to a proactive enabler of personalized care.

Assessing how the 2025 tariff landscape will reshape supply chains, procurement behaviors, and regional manufacturing strategies across the diagnostics value chain

Policy actions and trade measures can have substantial ripple effects across the diagnostics supply chain, and the cumulative impact of tariff adjustments announced for 2025 will be observed across manufacturing, distribution, and laboratory operations. Tariffs on imported reagents, instrument components, and consumables raise the marginal cost of production for manufacturers that rely on international suppliers, which can translate into higher list prices and contracting pressures. For laboratories and end users, this increases the importance of supply chain resilience, inventory planning, and the negotiation of long-term supplier agreements.

Moreover, tariffs can incentivize regionalization of production and procurement, prompting multinational manufacturers to reassess sourcing footprints and consider nearshoring or dual-sourcing strategies to mitigate exposure. In parallel, procurement teams within hospitals, ambulatory centers, and diagnostics networks may shift purchasing priorities toward suppliers with domestic manufacturing capabilities or established tariff-mitigation measures. Over time, these adjustments may accelerate consolidation among suppliers who can absorb cost variability and maintain service levels, while smaller vendors and reagent suppliers face increased pressure to optimize operations or form strategic alliances to preserve market access.

Targeted segmentation insights linking test modalities, assay technologies, allergen categories, and end-user operational priorities to commercial opportunities

Segment insights are essential for tailoring product development, commercialization, and adoption strategies. Based on test type, diagnostic pathways range from skin-based modalities such as intradermal and patch testing to serum-based approaches including serum-specific IgE assays and skin prick testing; within serum analyses, chemiluminescence immunoassay and enzyme-linked immunosorbent assay methods coexist with legacy radioallergosorbent techniques, each offering distinct trade-offs in throughput, sensitivity, and laboratory compatibility. Based on technology, assay selection further differentiates the market because chemiluminescence platforms tend to favor automation and sensitivity, enzyme-linked immunosorbent assays deliver flexibility and cost efficiency for mid-volume labs, fluorescent enzyme immunoassays offer multiplexing advantages in some configurations, and radioallergosorbent methods remain relevant where established workflows persist.

Based on allergen type, diagnostic requirements vary substantially: contact allergens and drug allergens often require tailored exposure histories and specialized panels, food allergens demand high specificity to minimize unnecessary avoidance, and inhalant allergens benefit from well-validated component testing to guide immunotherapy. Based on end user, operational imperatives differ between ambulatory care centers prioritizing rapid, clinic-friendly workflows; diagnostic laboratories focusing on throughput, reproducibility, and result interpretation; and hospitals and clinics that integrate diagnostics into acute and chronic care pathways and require robust reporting for complex patients. These segmentation lenses highlight where clinical demand, laboratory capability, and commercial models intersect and where targeted investment can drive adoption.

How divergent regional clinical practices, regulatory landscapes, and infrastructure investments create distinct adoption pathways across global markets

Regional dynamics influence both clinical practice and commercial strategies, requiring nuanced approaches to product design, regulatory engagement, and channel management. In the Americas, robust clinical adoption of advanced serum-based assays is paired with concentrated laboratory networks and strong payer scrutiny, which together demand demonstrable clinical utility and efficient reimbursement pathways. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and variable laboratory capacity mean that flexible product configurations, local partnerships, and support for decentralized testing can accelerate uptake, while regional clinical guidelines influence which allergen panels and assay formats are prioritized. In Asia-Pacific, rapid healthcare infrastructure investment, a growing prevalence of allergic conditions in urban centers, and diverse regulatory pathways create opportunities for both high-throughput centralized laboratories and point-of-care solutions adapted to local clinical workflows.

Taken together, these regional distinctions inform commercialization strategies, regulatory planning, and supply chain design, underscoring the importance of tailored evidence generation, localized service models, and partnerships with regional laboratory networks to achieve sustainable market penetration.

Key competitive behaviors and strategic priorities that determine which diagnostic providers will lead in laboratory adoption and clinical guideline integration

Competitive dynamics in allergy diagnostics are shaped by a mix of large diversified diagnostics firms, specialized allergy assay manufacturers, and agile niche players that focus on innovation or regional distribution. Established manufacturers invest in automation, multiplexing, and digital result interpretation to differentiate their portfolios and to meet laboratory demands for efficiency and integrated reporting. Specialized companies emphasize proprietary assay chemistries or clinical evidence supporting component-resolved diagnostics in order to drive adoption among allergists and tertiary care centers. Additionally, contract manufacturers and reagent suppliers play a critical role in maintaining supply continuity, particularly as laboratories seek partners capable of supporting validation and quality assurance under evolving regulatory expectations.

Strategic behaviors to watch include investments in partnerships with clinical networks and pharmacy chains for broader access, alliances with laboratory information system vendors to enhance result interoperability, and targeted evidence generation programs to secure favorable placement in clinical guidelines. Consolidation activity can be expected where scale enables improved pricing, distribution reach, and the ability to invest in next-generation assay development. New entrants that couple strong clinical data with scalable manufacturing and regulatory acumen will be well positioned to disrupt legacy business models.

Prioritized strategic initiatives for executives to strengthen evidence, interoperability, supply resilience, and go-to-market precision in allergy diagnostics

Industry leaders should prioritize a set of actionable initiatives to translate market dynamics into durable competitive advantage. First, invest in robust clinical evidence generation that demonstrates not only analytical performance but also clinical utility in guiding management decisions and reducing downstream healthcare utilization. Second, pursue platform interoperability and strong integration with laboratory information systems and electronic health records to streamline clinician workflows and enable value capture through decision support. Third, diversify supply chains and consider dual-sourcing or regional manufacturing arrangements to mitigate tariff exposure and ensure continuity of supply for critical reagents and instrument components.

Furthermore, adopt customer segmentation strategies that align commercial resources with the operational realities of ambulatory centers, high-throughput diagnostic laboratories, and integrated hospital systems. Complement product investments with scalable service offerings such as training, proficiency programs, and outcome tracking that lower adoption barriers. Finally, explore partnerships with therapeutics providers and allergy clinics to create bundled care pathways that link diagnostics to targeted interventions, thereby enhancing value propositions for payers and providers.

A transparent mixed-methods research approach integrating stakeholder interviews, regulatory review, and technical validation to underpin strategic recommendations

This analysis synthesizes findings derived from a rigorous mixed-methods research approach combining primary qualitative interviews with laboratory directors, practicing allergists, procurement leads, and industry executives alongside systematic secondary review of peer-reviewed literature, regulatory guidances, and technical documentation from assay manufacturers. Primary research emphasized triangulation across stakeholder groups to validate clinical workflows, assay preferences, and adoption barriers. Secondary sources provided context on technology performance characteristics, reimbursement environments, and historic regulatory precedents, which informed interpretation of stakeholder input and scenario development.

Data validation included cross-checking assay attributes and claimed performance characteristics against device labeling and regulatory summaries, while methodological transparency was maintained through clear documentation of inclusion criteria, interview protocols, and synthesis techniques. Limitations include variability across regional regulatory regimes and the evolving nature of trade policies, which may affect supply chain dynamics; these factors were addressed through scenario analysis and sensitivity checks to ensure robustness of recommendations. The result is a pragmatic evidence base designed to support strategic planning without relying on speculative forecasts.

Synthesis of actionable insights highlighting where technological advances, clinical expectations, and supply constraints intersect to inform strategic decisions

Allergy diagnostics is positioned at an inflection point where improved assay technologies, evolving clinical expectations, and supply chain realities converge to redefine how allergic disease is identified and managed. Precision in testing is enabling more effective patient stratification and targeted therapeutic pathways, while operational innovations are expanding capacity and improving turnaround. However, external pressures including trade policy shifts and regional heterogeneity in regulatory and reimbursement frameworks require proactive strategies around supply chain resilience, evidence generation, and localized commercialization.

Looking ahead, stakeholders who align product design with demonstrable clinical value, ensure interoperability with clinical systems, and adopt flexible manufacturing and distribution models will be best placed to capture opportunity and sustain adoption. Strategic collaboration between diagnostic providers, clinical networks, and payers will be crucial to translate diagnostic advances into measurable improvements in care pathways and patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Diagnostics Market, by Test Type

  • 8.1. Intradermal Test
  • 8.2. Patch Test
  • 8.3. Serum-Specific IgE Test
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme-Linked Immunosorbent Assay
    • 8.3.3. Radioallergosorbent Test
  • 8.4. Skin Prick Test

9. Allergy Diagnostics Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme-Linked Immunosorbent Assay
  • 9.3. Fluorescent Enzyme Immunoassay
  • 9.4. Radioallergosorbent Test

10. Allergy Diagnostics Market, by Allergen Type

  • 10.1. Contact Allergen
  • 10.2. Drug Allergen
  • 10.3. Food Allergen
  • 10.4. Inhalant Allergen

11. Allergy Diagnostics Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics

12. Allergy Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Allergy Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Allergy Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Allergy Diagnostics Market

16. China Allergy Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abnova Corporation
  • 17.6. ACON Laboratories, Inc.
  • 17.7. AESKU.GROUP GmbH
  • 17.8. bioMerieux SA
  • 17.9. Canon Inc.
  • 17.10. Danaher Corporation
  • 17.11. Eurofins Scientific SE
  • 17.12. EUROIMMUN Medizinische Labordiagnostika AG
  • 17.13. HAL Allergy Group B.V.
  • 17.14. Hitachi Chemical Diagnostics, Inc.
  • 17.15. HOB Biotech Group Corp., Ltd.
  • 17.16. Hollister Stier Allergy Inc.
  • 17.17. Hycor Biomedical (GmbH)
  • 17.18. HYCOR Biomedical Inc.
  • 17.19. Laboratory Corporation of America Holdings
  • 17.20. Lincoln Diagnostics, Inc.
  • 17.21. Macro Array Diagnostics GmbH
  • 17.22. Minaris Medical America, Inc.
  • 17.23. Neogen Corporation
  • 17.24. Omega Diagnostics Group PLC
  • 17.25. Quest Diagnostics Incorporated
  • 17.26. R-Biopharm AG
  • 17.27. Siemens Healthineers AG
  • 17.28. Stallergenes Greer International AG
  • 17.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)